The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Recent ELCC data released by J&J proves that the expanded adverse reactions seen during phase III trials of Mariposa can be managed. With approval expected mid-year, now is the time to pay attention
Kang Stem Biotech announced on Jan. 24 that it received final approval from the Japanese Ministry of Health, Labour and Welfare on Jan. 23 for its application for recognition of the manufacture of specific cell processed products.Through this approval, the company will receive adipose tissue from pa
Fundraising in the venture capital (VC) industry has completely frozen due to continued high interest rates. The number of large venture funds valued at more than 100 billion won, a barometer of a booming VC market, has fallen to just five in the first three quarters of this year. The figure was 17
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.With MARIPOSA trials displaying a significant improvement in OS, J&J expects the amivantamab+lazertinib combo to become a standard of care. The firm will file for FDA approval in 2023, and strive to
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.The MARIPOSA study has proven the feasibility of lazertinib+amivantamab as a standard first-line treatment. Competing trial FLAURA2 is expected to underperform in terms of OS. In addition, ESMO clini
The ongoing takeover battle for HMM, which had been a three-way competition between Harim Group, LX Group, and Dongwon Group, could face another twist. There’s speculation that POSCO might enter the acquisition fray, intensifying the competition among potential acquirers. Amid this, the prospective
Yuhan Pharmaceuticals’ lung cancer drug Leclaza has demonstrated enhanced efficacy when combined with Johnson & Johnson’s (J&J) lung cancer treatment. Detailed data is set to be presented at a global conference on Oct. 23, heightening market anticipation.According to industry sources on Oct. 4, Yuha
The author is an analyst for NH Investment & Securities. He can be reached at kyuha.lee@nhqv.com -- Ed.Phase III MARIPOSA meets primary endpointJanssen announced positive topline results from the pivotal phase III MARIPOSA study evaluating Rybrevant (amivantamab) in combination with lazertinib, a th
The author is an analyst for NH Investment & Securities. He can be reached at seungyeon.han@nhqv.com -- Ed.On Sep 26, the share price of HanAll Biopharma partner Immunovant jumped by over 97% on surprise interim data from the IMVT-1402 phase I trial. Encouraging results were reported in terms of bot
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Yuhan posted 2Q23 consolidated OP of W27.1bn, significantly beating consensus. Earnings should continue to improve on: 1) the likely listing of Lazertinib as a first-line treatment for NSCLC in Korea
Both domestic and global information technology (IT) giants are now joining pharmaceutical and biotech companies in utilizing artificial intelligence (AI) for drug development. Some AI drug development firms are currently in the process of going public through initial public offerings (IPOs).Accordi
Nextrade (NXT), a preparatory corporation for an alternative exchange, has received preliminary approval for an investment brokerage license from the Financial Services Commission (FSC) on July 19. As early as the beginning of 2025, it will be possible to trade listed stocks, such as Samsung Electro
The Korean government will announce a plan to ease special listing requirements for excellent companies with cutting-edge technologies in the semiconductor, bio, artificial intelligence, and secondary battery sectors in July.The Financial Services Commission (FSC) will map out the plan by forming a
The author is an analyst at NH Investment & Securities. He can be reached at dongyang.kim@nhqv.com -- Ed.In 2022, the NPS set aside 43.1% of its assets for responsible investment. At the NPS, responsible investment has become a key consideration for investment in a range of assets, including domesti
The author is an analyst of NH Investment & Securities. She can be reached at yd.yoon@nhqv.com -- Ed.For 1Q23, Kiwoom should report a significant jump in retail-related revenue, thanks to active stock trading by individual investors. In addition, PF provisioning should prove limited. Expecting it to
The author is an analysts of NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.At Yuhan, 1Q23 non-consolidated and consolidated OP likely came in at respective W14.6bn (beating consensus) and W13.3bn (missing consensus). We anticipate consolidated earnings improvement after com
The author is an analyst of NH Investment & Securities. She can be reached at yd.yoon@nhqv.com. -- Ed. MAVI’s strong connection with Mirae Asset affiliates (securities, capital) should prove favorable when it comes to creation of new funds next year. MAVI is striving to defend its earnings both thro
The number of cancelled IPOs in the South Korean stock market is likely to reach an all-time high this year. This year’s number is currently 13 according to the Korea Exchange.A total of 70 companies went public in the market this year, whereas the number was 91 last year. The scale of the IPOs decr
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Laser301 data were recently released at the ESMO Asia Congress 2022. Against this backdrop, attention is turning to Janssen’s commercialization strategy for Lazertinib. A competing phase III clinical
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. In 2022, healthcare stocks have been performing sluggishly in the NY stock market, affected by drastic absorption of market liquidity since early-2022. Given that 10-yr discounted cash flow is the mo